PBGENE-DMD has received Investigational New Drug clearance from the U.S. Food and Drug Administration (FDA) enabling initiation of clinical trial site activation. PBGENE-DMD was previously granted FDA ...

Empowering Clinical Research: SDC’s Sidekick™ AI Sets a New Standard for Intelligent Oversight ...

NES ZIONA, Israel, Feb. 17, 2026 /PRNewswire/ -- Amorphical, a developer of nano-amorphous mineral-based pharmacologic agents, today announced that long-term data from its Phase 2 trial in moderate-to ...

Live demonstrations of the Nanox.ARC will feature at the ECR booth #425 in Hall X4Oral presentation by Dr. Nogah Shabshin to present data on ...

Waystar Holding Corp. (NASDAQ:WAY) Q4 2025 Earnings Call Transcript February 17, 2026 Waystar Holding Corp. misses on earnings expectations. Reported EPS is $0.36 EPS, expectations were $0.39.

KalVista Pharmaceuticals, Inc. (Nasdaq: KALV) today announced the acceptance of three abstracts for presentation at the 2026 ...

A new post-hoc analysis from the LIBERTY studies, presented at ECCO 2026, demonstrated that initiating subcutaneous (SC) infliximab (Remsima™ SC) after a treatment interruption following intravenous ...

Managing bipolar I disorder (BD-I) is a long-term commitment, and factors such as symptoms and side effects influence ...

Tumor Shrinkage of 50% and significant CA-125 biomarker reduction observed at 220 mg dose levelPatient experienced only Grade 1 adverse events ...

In the RELIEVE UCCD LTE phase 2b study, duvakitug showed robust, durable efficacy for an additional 44 weeks in UC and CD ...

The 2026 International Stroke Conference (ISC), held February 4-6 in New Orleans, Louisiana, delivered potentially ...

Compass Pathways is rated a Hold due to high risk, funding needs, and the need for further data before reassessing the thesis ...